Chiome Bioscience focuses on addressing unmet medical needs through innovative drug discovery, particularly in the field of monoclonal antibodies (mAbs) for therapeutic applications. The company has developed a robust pipeline of products targeting various cancers and other diseases, utilizing advanced technologies to create first-in-class therapeutic antibodies. Notable products in their pipeline include ADCT-701, a humanized anti-DLK1 antibody-drug conjugate aimed at treating solid tumors, and CBA-1205, an enhanced antibody designed to improve antibody-dependent cellular cytotoxicity (ADCC) for difficult-to-treat cancers. Their research spans multiple phases, from basic research and preclinical studies to ongoing clinical trials, demonstrating a commitment to developing effective treatments for conditions with limited therapeutic options.

The proprietary ADLib® system is a cornerstone of Chiome's technology platform, enabling rapid and diverse antibody generation. This system leverages avian B cells to produce a wide variety of monoclonal antibodies in vitro, significantly reducing the time required for antibody selection to approximately ten days. The ADLib® system also allows for affinity maturation, enhancing the specificity and binding strength of antibodies through a unique process that does not rely on traditional genetic engineering methods. This innovative approach not only facilitates the creation of high-affinity antibodies but also expands the potential for therapeutic applications across various disease areas, including oncology and autoimmune disorders.

Japan

Chiome Bioscience Inc. designs, develops, and sells monoclonal antibody products for medicine, diagnosis, testing, and life sciences. Chiome Bioscience is a clinical stage biotechnology company. Chiome's focus is on discovery and development of antibody-based therapeutics.

Chiome Bioscience

Company Details